← Back to headlines
Apellis Pharmaceuticals Receives New 'Buy' Rating from Roth
Apellis Pharmaceuticals has received a new 'Buy' rating from Roth, based on positive prospects for its drug Syfovre.
13 Mar, 15:43 — 13 Mar, 15:43
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Farmers' Group Criticizes Proposed Pax Silica Economic Zone in Philippines
just now
Philippine President Marcos Orders P17.27 Billion for Classroom Construction
just now
Philippine President Marcos Pushes P46.22 Billion for Infrastructure Projects
just now